LUCID

  • Research type

    Research Study

  • Full title

    LUCID - LUng cancer CIrculating tumour Dna Study

  • IRAS ID

    143797

  • Contact name

    Nitzan Rosenfeld

  • Contact email

    nitzan.rosenfeld@cruk.cam.ac.uk

  • Sponsor organisation

    Cambridge University Hospitals NHS Foundation Trust R&D

  • Research summary

    This is a study to find out if regular blood tests might be useful for monitoring a patient's response to surgery or radical radiotherapy (with or without chemotherapy) in early stage lung cancer patients treated with curative intent.

    To date, there are no regular blood tests that can detect lung cancer. However, recent advances in technology mean that it is now possible to detect very tiny amounts of tumour genetic material in the blood, called circulating tumour-DNA (ctDNA). This method has been used successfully in patients with advanced lung cancer and we would now like to find out if it is helpful in early stage lung cancer patients undergoing curative treatment.

    The main aim of this study is to test whether ctDNA can be reliably detected in blood taken from early stage lung cancer patients treated with curative intent. In addition blood samples will be taken during treatment, at the end of treatment and for a 9 month follow-up period. The ctDNA levels will be compared across the samples and clinical features, to see if ctDNA could be used as a tool to predict a patient’s response to treatment and relapse.

    One hundred lung cancer participants planned for curative treatment will be recruited over an estimated time period of eighteen months. Surplus tissue from routine diagnostic or surgical biopsy samples will be analysed to identify tumour-specific genetic changes for each individual patient. Serial blood tests from each participant will then be tested to see if the specific tumour DNA changes identified can also be reliably detected in the blood.

    If ctDNA levels are detectable and changes during curative lung cancer treatment are observed, ctDNA could be used in future studies as a marker for the early detection of minimal residual disease and prediction of relapse and outcome.

  • REC name

    West Midlands - Coventry & Warwickshire Research Ethics Committee

  • REC reference

    14/WM/1072

  • Date of REC Opinion

    31 Jul 2014

  • REC opinion

    Further Information Favourable Opinion